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Key Clinical Message
We report here the clinical course of a Ph+ ALL patient who was treated with
ponatinib 15 mg/day, as maintenance therapy, and developed a BCR-ABL
T315I mutation leading to ALL relapse. This clonal evolution was reversed,
without adverse effects, by increasing ponatinib to 45 mg/day. To our knowl-
edge, we have been confronted with the first clinical case of a T315I clonal
selection of ALL caused by subeffective therapeutic level of the drug. This single
patient experience highlights the risk of T315I clone selection in Ph+ ALL trea-
ted with reduced dose ponatinib.
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Philadelphia positive (Ph+) acute lymphoblastic leukemia
(ALL) represents about 25% of B-lineage ALL in adults.
Chemotherapy combined with tyrosine kinase inhibitors
(TKIs) and allogeneic hematopoietic stem cell transplan-
tation (HSCT) in first remission has strongly improved
patient survival, with a 5-year overall survival rate about
60%. However, resistance to TKIs therapy represents a
clinically major issue [1]. Ponatinib is a third-generation
TKI approved for the treatment of chronic myeloid leuke-
mia (CML) or Ph+ ALL, with T315I mutation or resis-
tant/intolerant to other TKIs. On the basis of safety,
pharmacokinetics and pharmacodynamics data of a phase
1 study [1], 45 mg/day were identified as the recom-
mended dose for further clinical study. However, in a
subsequent phase 2 study with ponatinib 45 mg once
daily, serious vascular adverse events were reported [2]
causing early study termination by the FDA. Additional
cases of life-threatening vascular thrombotic events were
subsequently reported. Based on these data, experts rec-
ommended to minimize the use of ponatinib in Ph+ ALL
patient with significant cardiovascular risk factors and to
consider ponatinib dose reduction [3, 4].
Briefly, we report here the case of a 39-year-old patient
with a Ph+ ALL, without cardiovascular risk factors, who
presented after a second HSCT the emergence of a T315I
mutant clone under maintenance therapy with reduced
dose of ponatinib. The Ph+ ALL was initially treated with
chemotherapy and imatinib followed by HSCT. Four
years later, the Ph+ ALL relapsed and was treated with
second-generation TKIs (dasatinib, stopped because of
erythroderma, and then nilotinib) and donor lymphocyte
infusions (DLIs). Six months later, a second relapse was
treated with FLAG salvage chemotherapy, and a second
allogeneic HSCT followed by ponatinib 45 mg/day as
maintenance therapy (Fig. 1). Ponatinib was chosen
because of intolerance or resistance (sequencing did not
identify any classical mutation) to other available TKIs
(dasatinib, nilotinib, and bosutinib).
To decrease the risks of vascular thrombotic events, the
maintenance therapy was reduced to 15 mg/day, while
ALL was in complete molecular remission after
12 months of treatment at the dose of 45 mg/day. Six
months later, a molecular relapse was identified in bone
marrow (BCR-ABL/ABL ratio: 48%), and Sanger
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sequencing revealed a T315I mutation that was never doc-
umented in the previous analysis. The patient was treated
with steroids, a single dose of vincristine (1.4 mg/m2)
and ponatinib was increased to 45 mg once daily. Fifteen
days later, BCR-ABL/ABL ratio was reduced to 1.5% and
sequencing showed the concomitant presence of wild type
and T315I bcr-abl transcripts. DLIs were started. Three
months later, BCR-ABL/ABL ratio decreased to 0.025%,
and 6 months after the 2nd relapse, BCR-ABL transcript
was undetectable, without graft versus host disease
(GVHD). As we write this report, 15 months after the
2nd relapse, the patient is still in complete molecular
response. He presented a transient liver GVHD after the
3rd DLI. Ponatinib was stopped for 3 months and rein-
troduced at 30 mg/day due to thrombocytopenia and
liver toxicity (Fig. 1). Aspirin 100 mg/day was introduced
to try to reduce the risk of vascular complications, [3].
All other cardiovascular risk factors were closely moni-
tored and addressed if necessary [5]. After more than
31 months of ponatinib therapy, the arterial assessment
shows no sign of arteriopathy.
Primary or secondary ponatinib resistance is an
extremely rare event in chronic phase-CML. However,
ponatinib IC50 is much higher for T315I clones, and
intermediate dosage was shown to favor the outgrowth
of resistant clones harboring this mutation in vitro [6].
We postulate that our clinical observation correlates
with these in vitro data. The appearance of a T315I
clone under ponatinib 15 mg/day, and the achievement
of a complete molecular remission and extinction of
the T315I clone support this hypothesis and suggest
that ponatinib 45 mg/day may be the appropriate
dosage to treat T315I Ph+ ALL. Ph+ ALL is character-
ized with high cell proliferation and clone instability
that highly increase the risk of mutated clone emer-
gence, such as T315I clone. From our observation it
may be not advisable to treat Ph+ ALL patient with
low-dose ponatinib. In this setting, the risks of vascular
side effects should be viewed as acceptable considering
the lack of other therapeutic options for these high risk
patients. In the future, clinical dose finding trials are
highly needed to identify the appropriate intensity of
ponatinib treatment in induction and maintenance ther-
apy. Dose titration and management of vascular events
remain a major concern.
Authorship
JN: involved in manuscript redaction. MG: involved in
manuscript redaction. Stavroula Masouridi-Levrat :
involved in manuscript revision. MD: involved in manu-
script revision. OS: involved in manuscript revision.
Conflict of Interest
None declared.
0.001
0.01
0.1
1
10
100
B
C
R
-A
B
L/
A
B
L 
ra
tio
 (%
)
45 mg/d
HSCT and DLIs
Chemotherapy
Ponatinib 15 mg/d
30-45 mg/d
BCR-ABL
T315I 
clone
Figure 1. Disease course evolution after the 2nd Ph+ ALL relapse (1.12.2012) treated with FLAG salvage chemotherapy (■ fludarabine 30 mg/
m2/day+ cytarabine 2 g/m2/day (days 1–5) and G-CSF 5 mg/kg/day (FLAG)) followed by maintenance ponatinib (45 mg/day) after the second
HSCT (▲). After 12 months of complete molecular remission, ponatinib was reduced to 15 mg/day. Six months later, ALL relapsed (1.9.2014) and
T315I mutation were identified by Sanger sequencing. Ponatinib was immediately increased to 45 mg/day, and the patient received a unique
dose of 2 mg of Vincristine ( ) and three DLIs ( ) leading to rapid and persistent complete molecular response, bcr-abl transcript remaining
undetectable in bone marrow until today.
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